An interventional study of Thyroid Artery Embolization in Thyroid Nodules, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Not applicable, Interventional, and Treatment
Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.
This study is a prospective interventional cohort study.
The prospective cohort setting allows us to evaluate the direct effect of TAE on a series of patients on a longer period and to strengthen the retrospective data previously documented in other studies.
Included patients will have compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter.
They have to be Ineligible for surgery/ablative treatments or preference for TAE over other treatments.
There is no comparative group in our study as it aims to prove that TAE is effective and safe in a "nonsurgical" population, a population in which other alternatives lack or are refused by the patient.
Our sampling method will be a non-probabilistic convenience sampling. Patients will be recruited in an outpatient setting by the patient's treating endocrinologist or otolaryngologist.
207 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.
This study's planned enrollment of 20 is below the median of 75 across 121 interventional studies indexed under Thyroid Nodule.
Browse Thyroid Nodule studies →Centre de recherche du Centre hospitalier universitaire de Sherbrooke is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with diagnosis of Goiter with compressive symptoms in which other alternatives lack or are refused by the patient himself.
Procedure: Thyroid Artery Embolization
Interruption of blood flow that supplies thyroid nodule using embolization technique.
Change in Thyroid nodule volume
TAE effectiveness to reduce overall thyroid and nodular volumes in benign compressive goiters assessing changes in Nodule(s) volume(s) and Thyroid lobe volume.
Time frame: Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.
Change in symptoms after TAE.
Assess the impact of TAE on the symptoms related to the goiter as reported by the patient. Using ThyPRO score. ThyPRO is designed to evaluate physical, psychological, and social impairments caused by benign thyroid diseases by evaluating : * Symptom severity * Functional limitations * Emotional and social impacts * This disease-specific focus supports patient-centered care, clinical decision-making, and outcomes research. * Target Population ThyPRO is validated for adults aged 18 and older with benign thyroid diseases. The ThyPRO consists of 85 items, grouped into: 13 multi-item domains: Goiter symptoms (11 items) Hyperthyroid symptoms (8) Hypothyroid symptoms (4) Eye symptoms (8) Tiredness (7) Cognitive impairment (6) Anxiety (6), Depressivity (7) Emotional susceptibility (9) Impaired social life (4), daily life (6), and sex life (2) Cosmetic complaints (6) 1 global QoL item Each question is rated on a 5-point Likert scale (0 = Not at all to 4 = Completely
Time frame: Follow-ups at 3 months, 6 months and 12 months post-op.
Safety level of TAE in compressive goiter: Adverse Events report
Evaluate the safety of TAE for the treatment of benign compressive goiter using the Adverse Events report.
Time frame: Day of embolisation; Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.
Safety level of TAE in compressive goiter: thyroid function tests
Monitoring of the effect of the intervention with thyroid function tests.
Time frame: At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.
Safety level of TAE in compressive goiter: parathyroid function tests
Describe the effect of the procedure on parathyroid function with PTH and calcium blood levels.
Time frame: At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.
Plan to share: No — IPD information will only be shared after a formal request sent to the principal investigator's email address if the latter considers that the request is legally scientifically justified.
Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.
Of 67 non-industry interventional studies with no phase under Thyroid Nodule, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 43 months is above that.
Counting every sponsor, half of 71 studies reached it within 30 months; a quarter within 14 and three quarters within 46.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → May 2026, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke